Théa Signs License Option Agreement for Elsalys’ Retinal Candidate

March 2, 2018: By Joan McKenna

France-based Théa Laboratories has signed a license option agreement for Elsalys Biotech’s ELB011 program in ophthalmology, Elsalys announced Feb. 22.

Elsalys describes ELB011 as a first-in-class antibody that demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause certain retinal diseases, including age-related macular degeneration (AMD).

Target diseases for ELB011 are wet AMD, proliferative diabetic retinopathy, and diabetic macular edema.

Under the agreement, Théa will pay Elsalys an up-front payment of an undisclosed amount, plus milestone payments and royalties on sales. Théa said its exercise of the option could take place by the end of 2018.

Elsalys, a new French company focused on immuno-oncology, will remain in charge of the initial steps of preclinical development and the production of batches for toxicology studies and clinical trials. Théa will be responsible for full clinical development and commercialization in ophthalmology.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023